文献速递银屑病与炎症性皮肤病

SGLT2抑制剂在银屑病合并2型糖尿病患者中的疗效与安全性:基于人群的目标试验模拟

Efficacy and safety of sodium-glucose cotransporter-2 inhibitors in patients with psoriasis and comorbid type 2 diabetes: A population-based target trial emulation.
PubMed 文献 · J Am Acad Dermatol · 2026-02-06

该目标试验模拟纳入银屑病合并2型糖尿病成人,比较SGLT2i与DPP4i及GLP1RA的临床结局。SGLT2i较DPP4i显著降低全因死亡、急诊就诊及肾脏不良结局风险;较GLP1RA降低哮喘、抑郁、睡眠障碍及恶性肿瘤风险。

要点

  • SGLT2i较DPP4i降低全因死亡(HR=0.633)、急诊就诊及肾脏不良结局风险。
  • SGLT2i较GLP1RA降低哮喘、抑郁、睡眠障碍及恶性肿瘤风险。
  • 结果支持SGLT2i作为银屑病合并2型糖尿病患者的辅助治疗进一步研究。

核心结论

  • 在银屑病合并2型糖尿病患者中,SGLT2i治疗与 favorable 临床结局相关,支持其作为辅助治疗进一步研究。

研究设计与样本

  • 目标试验模拟纳入2013至2025年间启动SGLT2i、DPP4i或GLP1RA的银屑病合并2型糖尿病成人。
  • SGLT2i启动者分别与DPP4i及GLP1RA启动者进行倾向评分匹配。
  • 采用Cox比例风险回归计算结局的风险比(HR)及95%置信区间(95%CI)。

主要发现

  • 共纳入8799例SGLT2i启动者与8799例匹配的DPP4i启动者,以及11550例SGLT2i启动者与11550例匹配的GLP1RA启动者。
  • 与DPP4i相比,SGLT2i与较低的全因死亡(HR=0.633,95%CI=0.564-0.711)、急诊就诊(HR=0.915,95%CI=0.871-0.961)、急性肾损伤(HR=0.834,95%CI=0.759-0.916)、慢性肾病(HR=0.866,CI=0.791-0.949)、终末期肾病(HR=0.555,95%CI=0.438-0.703)及严重脓毒症(HR=0.689,CI=0.594-0.799)风险相关。
  • 与GLP1RA相比,SGLT2i与较低的哮喘(HR=0.822,95%CI=0.713-0.946)、抑郁(HR=0.887,CI=0.801-0.983)、睡眠障碍(HR=0.856,CI=0.783-0.936)及恶性肿瘤(HR=0.852,95%CI=0.764-0.951)风险相关。

临床怎么用

  • 对于银屑病合并2型糖尿病患者,SGLT2i可能作为辅助治疗选择,尤其关注肾脏及代谢相关结局时。

局限性

  • 回顾性设计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) offer cardiorenal benefits in patients with type 2 diabetes mellitus (T2DM). OBJECTIVE: To evaluate safety and effectiveness of SGLT2i in improving clinical outcomes in patients with psoriasis and comorbid T2DM, compared with dipeptidyl peptidase-4 inhibitors (DPP4i) and glucagon-like peptide-1 receptor agonists (GLP1RA). METHODS: This emulated target trial included adults with psoriasis and T2DM initiating SGLT2i, DPP4i, or GLP1RA between 2013 and 2025. SGLT2i initiators were propensity score-matched to DPP4i initiators and GLP1RA initiators, respectively. Cox proportional hazards regression was used to calculate hazard ratios (HRs) and 95% confidence intervals (95% CIs) of the outcomes. RESULTS: A total of 8799 SGLT2i initiators and 8799 matched DPP4i initiators with psoriasis and comorbid T2DM, and 11,550 SGLT2i initiators and 11,550 matched GLP1RA initiators, were included. Compared with DPP4i, treatment with SGLT2i was associated with significantly lower all-cause mortality (HR = 0.633, 95% CI = 0.564-0.711) and reduced risks of emergency visits (HR = 0.915, 95% CI = 0.871-0.961), acute kidney injury (HR = 0.834, 95% CI = 0.759-0.916), chronic kidney disease (HR = 0.866, CI = 0.791-0.949), end-stage renal disease (HR = 0.555, 95% CI = 0.438-0.703), and severe sepsis (HR = 0.689, CI = 0.594-0.799). Compared with GLP1RA, treatment with SGLT2i was associated with reduced risks of asthma (HR = 0.822, 95% CI = 0.713-0.946), depression (HR = 0.887, CI = 0.801-0.983), sleep disorders (HR = 0.856, CI = 0.783-0.936), and malignancies (HR = 0.852, 95% CI = 0.764-0.951). LIMITATIONS: Retrospective design. CONCLUSION: Treatment with SGLT2i was associated with favorable clinical outcomes in patients with psoriasis and comorbid T2DM. These findings support investigation of SGLT2i as an adjunct therapy in this population.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Cheng D, Ji H, Theodosakis N, et al. Efficacy and safety of sodium-glucose cotransporter-2 inhibitors in patients with psoriasis and comorbid type 2 diabetes: A population-based target trial emulation. J Am Acad Dermatol. 2026. PMID: 41655841. doi:10.1016/j.jaad.2026.02.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。